# Galleon Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/galleon-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Horsham, US
- Website: www.galleonpharma.com
- Total disclosed funding: $61M
- Latest round: Series B (Nov 19, 2014)
- Investors on record: 5

## About

Galleon Pharmaceuticals, Inc. is a domain name services company that specializes in facilitating secure domain ownership transactions, offering both direct sales and leasing options to clients worldwide.Founded in 2003 and headquartered in Horsham, Pennsylvania, Galleon Pharmaceuticals, Inc. operates within the domain name sector, providing clients with secure domain purchasing and leasing solutions. The company has successfully completed 7 deals and recently secured USD 24.92 mn in funding through the Series B round, which included investors like BioAdvance and Morgenthaler Ventures. Their total amount raised stands at USD 24.92 mn, with a current company valuation of USD 78.69 mn.Galleon Pharmaceuticals specializes in the sale and leasing of domain names, offering a core product of domain ownership. Customers can purchase domains outright for a fixed price of USD 19,888 or choose a Lease to Own arrangement at USD 1,683 per month. The service caters to a diverse clientele, including businesses and individuals establishing a digital presence. Galleon Pharmaceuticals ensures secure transaction support and offers local currency options at checkout to accommodate international clients, targeting markets globally.Revenue for Galleon Pharmaceuticals is generated through its domain sales and leasing options. The primary revenue model includes direct sales of domain names and monthly leasing arrangements. The flagship domain priced at USD 19,888 serves as a key revenue contributor, while the Lease to Own option enhances access to digital assets. The company’s transaction structure is designed for efficiency, utilizing secure payment gateways to facilitate transactions for both B2B and direct-to-consumer clients.Galleon Pharmaceuticals is focused on expanding its product lines and enhancing its market reach. Upcoming initiatives include the launch of new domain offerings aimed at both established businesses and startups. The recent funding from the Series B round will support these developments and bolster the company’s marketing efforts. The firm also plans to target specific international markets for expansion, with timelines subject to detailed strategic planning.

## Funding rounds

- Series B, Nov 19, 2014, $25M — Morgenthaler Ventures, BioAdvance
- Series B, Nov 15, 2010, $10M — HealthCare Ventures, Morgenthaler Ventures, TPG Biotech, BioAdvance
- Series B, Dec 1, 2008, $15M — Morgenthaler Ventures
- Series A, Feb 9, 2007, $11M — HealthCare Ventures, Morgenthaler Ventures, TPG
- Seed, Feb 1, 2005, $0.5M — BioAdvance

## Investors

- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Seed, Series B
- HealthCare Ventures — Series A, Series B
- Morgenthaler Ventures (https://capitalatlas.ai/funds/morgenthaler-ventures) — Series A, Series B
- TPG (https://capitalatlas.ai/funds/tpg) — Series A
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series B